Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment

Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment

More than ten years after the approval of ipilimumab, immune checkpoint inhibitors (ICIs) against PD-1 and CTLA-4 have been established as the most effective treatment for locally advanced or metastatic melanoma, achieving durable responses either as monotherapies or in combinatorial regimens. Howev...

Full description

Bibliographic Details
Main Authors: Dimitrios C. Ziogas, Charalampos Theocharopoulos, Panagiotis-Petros Lialios, Dimitra Foteinou, Ioannis-Alexios Koumprentziotis, Georgios Xynos, Helen Gogas
Format: Article
Language:English
Published: MDPI AG 2023-05-01
Series:Cancers
Subjects:
immune checkpoints
immune checkpoint inhibitors
melanoma
immunotherapy resistance
relatlimab
LAG-3
Online Access:https://www.mdpi.com/2072-6694/15/10/2718

Internet

https://www.mdpi.com/2072-6694/15/10/2718

Similar Items